P5091

09/11/2012 - "In animal tumor model studies, P5091 is well tolerated, inhibits tumor growth, and prolongs survival. "
01/01/2019 - "Furthermore, P5091 treatment caused FOXP3 loss in Treg cells decreased the proportion of Treg cells in tumor bearing mice. "
01/01/2019 - "CT26 xenografts model was employed to examine the anti-tumor effect of P5091. "
01/01/2017 - "Previously, we reported the P5091 series of small molecule USP7 inhibitors and demonstrated their direct anti-tumor activity in vivo using xenograft models. "
01/01/2019 - "Our study here showed that P5091 may be a candidate for cancer immunotherapy."

01/01/2017 - "Therefore, in this study, we assessed the influence of its inhibitor P5091 on ovarian cancer cells. "
01/01/2017 - "P5091 shows efficacy in suppressing ovarian cancers harbouring wild-type and mutant p53. "
01/01/2017 - "Ovarian cancer cells were treated with P5091, and cell proliferation was measured with MTT assay; cell morphology was inspected under a phase-contrast microscope; cell cycle and cell death were examined by flow cytometry. "
01/01/2017 - "The USP7 Inhibitor P5091 Induces Cell Death in Ovarian Cancers with Different P53 Status."
01/01/2017 - "P5091 effectively suppressed the growth of ovarian cancer cells, caused cell cycle blockage, and induced necrosis and apoptosis with more severe phenotypes observed in HeyA8 cells with wild-type p53 than in OVCAR-8 cells with mutant p53. "

12/01/2020 - "The USP7 specific inhibitor P5091 may accelerate the degradation of β-catenin by enhancing its ubiquitination, reduce lung epithelial-mesenchymal transition, and thus exert a certain protective effect against hyperoxic lung injury."

01/01/2017 - "USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth."

01/01/2018 - "The USP7 inhibitor, P5091, and the Wip1/PPM1D inhibitor, GSK2830371, decreased the viability of Ewing sarcoma cells. "